Welcome to our dedicated page for HUTCHMED (China) SEC filings (Ticker: HMDCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HUTCHMED (China)'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HUTCHMED (China)'s regulatory disclosures and financial reporting.
HUTCHMED has begun a global Phase I/IIa clinical trial of HMPL-A580, its second next-generation Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient was dosed on March 4, 2026.
HMPL-A580 links a highly selective PI3K/PIKK small-molecule inhibitor to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade. The study’s dose-escalation phase will determine the recommended dose, followed by expansion cohorts to further assess safety and preliminary anti-tumor activity.
HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.
Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.